Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies

  • Kalko, S.G.
  • Paco, S.
  • Jou, C.
  • Rodríguez, M.A.
  • Meznaric, M.
  • Rogac, M.
  • Jekovec-Vrhovsek, M.
  • Sciacco, M.
  • Moggio, M.
  • Fagiolari, G.
  • De Paepe, B.
  • De Meirleir, L.
  • Ferrer, I.
  • Roig-Quilis, M.
  • Munell, F.
  • Montoya, J.
  • López-Gallardo, E.
  • Ruiz-Pesini, E.
  • Artuch, R.
  • Montero, R.
  • Torner, F.
  • Nascimento, A.
  • Ortez, C.
  • Colomer, J.
  • Jimenez-Mallebrera, C.
Background Mutations in the gene encoding thymidine kinase 2 (TK2) result in the myopathic form of mitochondrial DNA depletion syndrome which is a mitochondrial encephalomyopathy presenting in children. In order to unveil some of the mechanisms involved in this pathology and to identify potential biomarkers and therapeutic targets we have investigated the gene expression profile of human skeletal muscle deficient for TK2 using cDNA microarrays. Results We have analysed the whole transcriptome of skeletal muscle from patients with TK2 mutations and compared it to normal muscle and to muscle from patients with other mitochondrial myopathies. We have identified a set of over 700 genes which are differentially expressed in TK2 deficient muscle. Bioinformatics analysis reveals important changes in muscle metabolism, in particular, in glucose and glycogen utilisation, and activation of the starvation response which affects aminoacid and lipid metabolism. We have identified those transcriptional regulators which are likely to be responsible for the observed changes in gene expression. Conclusion Our data point towards the tumor suppressor p53 as the regulator at the centre of a network of genes which are responsible for a coordinated response to TK2 mutations which involves inflammation, activation of muscle cell death by apoptosis and induction of growth and differentiation factor 15 (GDF-15) in muscle and serum. We propose that GDF-15 may represent a potential novel biomarker for mitochondrial dysfunction although further studies are required.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy

  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Badosa, Carmen
  • Madruga-Garrido, Marcos
  • Martí, Itxaso|||0000-0003-0578-9568
  • Paradas, Carmen|||0000-0002-6917-2236
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Berardo, Andres
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Trifunov, Selena|||0000-0002-1807-9621
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Kalko, Susana G.|||0000-0002-6701-0233
  • Blázquez-Bermejo, Cora
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Mavillard, Fabiola|||0000-0002-1460-0483
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Montoya, Julio|||0000-0003-1770-6299
  • Ruiz-Pesini, Eduardo|||0000-0002-0269-7337
  • Villarroya, Joan
  • Montero, Raquel|||0000-0003-0609-5701
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Artuch, R.|||0000-0002-3422-9685
  • Hirano, Michio|||0000-0002-7070-7402
  • Nascimento, Andrés
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1-49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Late-onset thymidine kinase 2 deficiency, a review of 18 cases

  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Hernández-Laín, Aurelio
  • Rivas, Eloy
  • Hernández Voth, Ana
  • Sayas Catalán, Javier
  • Fernández-Torrón, Roberto
  • Fuiza-Luces, Carmen
  • García García, Jorge
  • Morís, Germán|||0000-0001-7608-2194
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Miralles, Francesc
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Caballero Sahelices, Concesa
  • Méndez Ferrer, Bosco
  • Martí, Ramon A.|||0000-0002-8273-9540
  • García Arumí, Elena|||0000-0003-1848-005X
  • Badosa, María Carmen
  • Esteban-Pérez, Jesús
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Encinar, Alberto Blazquez
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Hirano, Michio|||0000-0002-7070-7402
  • Martin, Miguel Ángel
  • Paradas, Carmen|||0000-0002-6917-2236
TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the 'myopathic form' of the mitochondrial depletion/multiple deletions syndrome, with a wide spectrum of severity. We describe 18 patients with mitochondrial myopathy due to mutations in the TK2 gene with absence of clinical symptoms until the age of 12. The mean age of onset was 31 years. The first symptom was muscle limb weakness in 10/18, eyelid ptosis in 6/18, and respiratory insufficiency in 2/18. All patients developed variable muscle weakness during the evolution of the disease. Half of patients presented difficulty in swallowing. All patients showed evidence of respiratory muscle weakness, with need for non-invasive Mechanical Ventilation in 12/18. Four patients had deceased, all of them due to respiratory insufficiency. We identified common radiological features in muscle magnetic resonance, where the most severely affected muscles were the gluteus maximus, semitendinosus and sartorius. On muscle biopsies typical signs of mitochondrial dysfunction were associated with dystrophic changes. All mutations identified were previously reported, being the most frequent the in-frame deletion p.Lys202del. All cases showed multiple mtDNA deletions but mtDNA depletion was present only in two patients. The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transcriptome Analysis of Ullrich Congenital Muscular Dystrophy Fibroblasts Reveals a Disease Extracellular Matrix Signature and Key Molecular Regulators

  • Paco Mercader, Sonia|||0000-0002-7151-8144
  • Casserras, Teresa
  • Rodríguez, Maria Angels
  • Jou, Cristina|||0000-0002-2223-7880
  • Puigdelloses, Montserrat
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Colomer, Jaume
  • Nascimento, Andrés
  • Kalko, Susana G.|||0000-0002-6701-0233
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
Collagen VI related myopathies encompass a range of phenotypes with involvement of skeletal muscle, skin and other connective tissues. They represent a severe and relatively common form of congenital disease for which there is no treatment. Collagen VI in skeletal muscle and skin is produced by fibroblasts. In order to gain insight into the consequences of collagen VI mutations and identify key disease pathways we performed global gene expression analysis of dermal fibroblasts from patients with Ullrich Congenital Muscular Dystrophy with and without vitamin C treatment. The expression data were integrated using a range of systems biology tools. Results were validated by real-time PCR, western blotting and functional assays. We found significant changes in the expression levels of almost 600 genes between collagen VI deficient and control fibroblasts. Highly regulated genes included extracellular matrix components and surface receptors, including integrins, indicating a shift in the interaction between the cell and its environment. This was accompanied by a significant increase in fibroblasts adhesion to laminin. The observed changes in gene expression profiling may be under the control of two miRNAs, miR-30c and miR-181a, which we found elevated in tissue and serum from patients and which could represent novel biomarkers for muscular dystrophy. Finally, the response to vitamin C of collagen VI mutated fibroblasts significantly differed from healthy fibroblasts. Vitamin C treatment was able to revert the expression of some key genes to levels found in control cells raising the possibility of a beneficial effect of vitamin C as a modulator of some of the pathological aspects of collagen VI related diseases.